Fact Sheet

What makes Valeant different?

PhRMA October 30, 2015

Much like Turing, Valeant Pharmaceutical’s strategy is more reflective of a hedge fund than an innovative biopharmaceutical company. Valeant invests on average less than 3% of its total revenue on R&D. PhRMA member companies invest on average 20% of total revenue on R&D. PhRMA member companies invest on average 20% of total revenue on R&D. This significant investment reflects our member companies’ long history of drug discovery and innovation resulting in increased longevity and improved lives for millions of patients.

Download